A5012689870- Cervical Cancer and HPV Research
- Breast Cancer Treatment Studies
- Lysosomal Storage Disorders Research
- Genital Health and Disease
- Science and Education Research
- Carbohydrate Chemistry and Synthesis
- Urological Disorders and Treatments
- Glycogen Storage Diseases and Myoclonus
- Estrogen and related hormone effects
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Molecular Biology Techniques and Applications
- Sperm and Testicular Function
- Metastasis and carcinoma case studies
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Reproductive Biology and Fertility
- NF-κB Signaling Pathways
- DNA Repair Mechanisms
- Women's cancer prevention and management
- Genomics and Chromatin Dynamics
- Endometrial and Cervical Cancer Treatments
- Youth, Drugs, and Violence
- Cancer Risks and Factors
Universidade de Caxias do Sul
2008-2024
Universidad de Las Palmas de Gran Canaria
2010
Fertility Medical Group
2008
Universidade Federal do Rio Grande do Sul
2001-2002
Hospital de Clínicas de Porto Alegre
2001-2002
This paper aimed at studying the transplacental transmission of HPV and looking epidemiological factors involved in maternal viral infection. The following sampling methods were used: (1) pregnant woman, (a) genital; (b) peripheral blood; (2) newborn, oral cavity, axillary inguinal regions; nasopharyngeal aspirate, (c) cord (3) placenta. DNA was identified using two methods: multiplex PCR human beta-globin PGMY09 PGMY11 primers; nested-PCR, which combines degenerated primers E6/E7 regions...
The purpose was to study the perinatal transmission of human papillomavirus DNA (HPV-DNA) in 63 mother-newborn pairs, besides looking at epidemiological factors involved viral transmission. following sampling methods were used: (1) pregnant woman, when recruited, cervix and clinical lesions vagina, vulva perineal region; (2) newborn, (a) buccal, axillary inguinal regions; (b) nasopharyngeal aspirate, (c) cord blood; (3) children, buccal repeated 4th week 6th 12th month life. HPV-DNA...
Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy estrogen receptor-positive advanced breast cancer and have been recognized as a prognostic predictive biomarker well potential therapeutic target. However, prevalence ESR1m real-world patients has not adequately described. Therefore, we sought evaluate metastatic samples from Brazilian with (ER+) previously treated therapy. The presence was evaluated formalin-fixed paraffin-embedded (FFPE) tissue...
The purpose of the present study was to identify expression p16INK4 in cervical cancer precursor lesions by immunohistochemistry and correlate it with lesion grade presence human papillomavirus (HPV) infection. Cervical specimens from 144 women seen consecutively at gynecology outpatient clinic our institution December 2003 May 2005 were analyzed cytopathology, histopathology, polymerase chain reaction for HPV-DNA, immunostaining. Histologically normal biopsies, HPV-DNA negative reaction,...
Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy estrogen receptor-positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, well predictive prognostic biomarker. Nonetheless, role ESR1m possible mechanism primary resistance, whether it also occurs tumors that resistant ET administered early-stage disease (neo)adjuvant, has not adequately studied. In this study, we evaluated prevalence tumor...
In the present work effect of drug treatment on different lymphocyte populations in chronic lymphocytic leukemia was studied. During therapy there evidence an increased number cells unidentifiable by conventional surface markers, provisionally termed surface‐marker‐negative cells. addition, numbers T lymphocytes untreated patients and further IgG were obtained.
Abstract Background: Breast cancer (BC) with low expression of HER2 (HER2-low) might constitute a group tumors unique clinical and biological characteristics. However, the prognostic impact HER2-low status vs HER2-zero in terms pathological complete response (pCR) event-free survival (EFS) after neoadjuvant chemotherapy (NACT) remains controversial. The aim this study was to evaluate pCR EFS rates early BC patients treated NACT. Methods: In cross-sectional study, we analyzed 565 consecutive...
Abstract Background: Breast cancer (BC) with low expression of HER2 (HER2-low) might constitute a group tumors unique clinical and biological characteristics. Little is known about axillary downstaging nodal surgical outcomes in HER2-low BC after neoadjuvant chemotherapy (NACT). The aim this study was to evaluate response management the axilla patients submitted NACT. Methods: In cross-sectional single center study, we consecutively included all diagnosed early HER2-negative between 2017...
Genome-wide analysis using microarrays has revolutionized breast cancer (BC) research. A substantial body of evidence supports the clinical utility 21-gene assay (Oncotype DX) and 70-gene (MammaPrint) to predict BC recurrence magnitude benefit from chemotherapy. However, there is currently no genetic tool able chemosensitivity chemoresistance neoadjuvant chemotherapy (NACT) during treatment. In this study, we explored predictive value DNA repair gene expression in setting. We selected 98...
Abstract Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy (ET) estrogen receptor-positive (ER+) advanced breast cancer and have been recognized as a prognostic predictive biomarker well potential therapeutic target. ESR1m prevalence has described 9-45% cohorts ET-resistant metastatic tumors variety publications. We recently reported 25% cohort ER+ patients with visceral metastasis. However, role mechanism ET used early-stage disease...
e12538 Background: Genome-wide analysis using microarrays has revolutionized the field of breast cancer (BC) research, classifying by gene expression profiling. In patients with BC, a substantial body evidence supports clinical utility For example, 21-gene assay (Oncotype DX) and 70-gene (MammaPrint) predict BC recurrence magnitude chemotherapy benefit. However, there is currently no gene-expression profiling able to chemosensitivity chemoresistance neoadjuvant (NACT) during treatment....